Refractory and relapsed hairy-cell leukemia (HCL): casting light on promising experimental drugs in clinical trials

References

• Bouroncle BA, Wiseman BK, Doan CA. Leukemic reticuloendotheliosis. Blood. 1958;13:609–630.
   PubMed Web of Science ®Google Scholar
• Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lym-phoid tissues: report of the clinical advisory committee meeting -Airlie house, Virginia, November 1997. J Clin Oncol. 1999;17:3835–3849.
   PubMed Web of Science ®Google Scholar
• Grever MR, Abdel-Wahab O, Andritsos LA, et al. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood. 2017;129:553–560.
   PubMed Web of Science ®Google Scholar
• Robak T, Matutes E, Catovsky D, et al. Hairy cell leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v100–107.
   PubMedGoogle Scholar
• Andritsos LA, Grever MR. Historical overview of hairy cell leukemia. Best Pract Res Clin Haematol. 2015;28:166–174.
   PubMed Web of Science ®Google Scholar
• Teras LR, DeSantis CE, Cerhan JR, et al. US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66:443.
   PubMed Web of Science ®Google Scholar
• Tadmor T, Polliack A. Epidemiology and environmental risk in hairy cell leukemia. Best Pract Res Clin Haematol. 2015;28:175–179.
   PubMed Web of Science ®Google Scholar
• Oscier D, Stamatopoulos K, Mirandari A, et al. The genomics of hairy cell leukaemia and splenic diffuse red pulp lymphoma. Cancers (Basel). 2022;29(14):697.
   Google Scholar
• Monnereau A, Slager SL, Hughes AM, et al. Medical history, lifestyle, and occupational risk factors for hairy cell leukemia: the interlymph non-Hodgkin lymphoma subtypes project. J Natl Cancer Inst Monogr. 2014;2014:115–124.
   PubMedGoogle Scholar
• Orsi L, Delabre L, Monnereau A, et al. Occupational exposure to pesticides and lymphoid neoplasms among men: results of a French case-control study. Occup Environ Med. 2009;66:291–298.
   PubMed Web of Science ®Google Scholar
• Stewart DJ, Keating MJ. Radiation exposure as a possible etiologic factor in hairy cell leukemia (leukemic reticuloendotheliosis). Cancer. 1980;46:1577–1580.
   PubMed Web of Science ®Google Scholar
• Colovic MD, Jankovic GM, Wiernik PH. Hairy cell leukemia in first cousins and review of the literature. Eur J Haematol. 2001;67:185–188.
   PubMed Web of Science ®Google Scholar
• Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011;364:2305–2315.
   PubMed Web of Science ®Google Scholar
• Tiacci E, Schiavoni G, Forconi F, et al. Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation. Blood. 2012;119:192–195.
   PubMed Web of Science ®Google Scholar
• Xi L, Arons E, Navarro W, et al. Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation. Blood. 2012;119:3330–3332.
   PubMed Web of Science ®Google Scholar
• Kreitman RJ. Hairy cell leukemia: present and future directions. Leuk Lymphoma. 2019;60:2869–2879.
   PubMed Web of Science ®Google Scholar
• Puła A, Robak T. Hairy cell leukemia: a brief update on current knowledge and treatment prospects. Curr Opin Oncol. 2021;33:412–419.
   PubMedGoogle Scholar
• Tadmor T, Polliack A. Hairy cell leukemia: uncommon clinical features, unusual sites of involvement and some rare associations. Best Pract Res Clin Haematol. 2015;28(4):193–199.
   PubMedGoogle Scholar
• Robak E, Jesionek-Kupnicka D, Robak T. Skin changes in hairy cell leukemia. Ann Hematol. 2021;100:615–625.
   PubMed Web of Science ®Google Scholar
• Robak P, Jesionek-Kupnicka D, Kupnicki P, et al. Bone lesions in hairy cell leukemia: diagnosis and treatment. Eur J Haematol. 2020;105:682–691.
   PubMedGoogle Scholar
• Maitre E, Cornet E, Salaün V, et al. Immunophenotypic analysis of hairy cell leukemia (HCL) and hairy cell leukemia-like (HCL-like) disorders. Cancers (Basel). 2022;14:1050.
   PubMed Web of Science ®Google Scholar
• Summers TA, Jaffe ES. Hairy cell leukemia diagnostic criteria and differential diagnosis. Leuk Lymphoma. 2011;52(Suppl 2):6–10.
   PubMedGoogle Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–2390.
   PubMed Web of Science ®Google Scholar
• Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36:1720–1748.
   PubMed Web of Science ®Google Scholar
• Falini B, Martino G, Lazzi S. A comparison of the international consensus and 5th World Health Organization classifications of mature B-cell lymphomas. Leukemia. 2022 Dec 2. DOI:10.1038/s41375-022-01764-1.
   Google Scholar
• Campo E, Jaffe ES, Cook JR, et al. The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee. Blood. 2022;140:1229–1253.
   PubMed Web of Science ®Google Scholar
• Robak T. Hairy-cell leukemia variant: recent view on diagnosis, biology and treatment. Cancer Treat Rev. 2011;37:3–10.
   PubMed Web of Science ®Google Scholar
• Matutes E. Diagnostic and therapeutic challenges in hairy cell leukemia-variant: where are we in 2021? Expert Rev Hematol. 2021;14:355–363.
   PubMed Web of Science ®Google Scholar
• Chandran R, Gardiner SK, Smith SD, et al. Improved survival in hairy cell leukaemia over three decades: a SEER database analysis of prognostic factors. Br J Haematol. 2013;163:407–409.
   PubMed Web of Science ®Google Scholar
• Bohn JP, Neururer S, Pirklbauer M, et al. Hairy cell leukemia patients have a normal life expectancy- A 35-year single-center experience and comparison with the general population. Cancers (Basel). 2022 Feb 28;14:1242.
   PubMedGoogle Scholar
• Benz R, Arn K, Andres M, et al. Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial. Blood Adv. 2020;4:3699–3707.
   PubMed Web of Science ®Google Scholar
• Chadha P, Rademaker AW, Mendiratta P, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-termfollow-up of the Northwestern University experience. Blood. 2005;106:241–246.
   PubMed Web of Science ®Google Scholar
• Saven A, Burian C, Koziol JA, et al. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood. 1998;92:1918–1926.
   PubMed Web of Science ®Google Scholar
• Else M, Dearden CE, Matutes E, et al. Long term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol. 2009;145:733–740.
   PubMed Web of Science ®Google Scholar
• Troussard X, Maître E, Cornet E. Hairy cell leukemia 2022: update on diagnosis, risk-stratification, and treatment. Am J Hematol. 2022;97:226–236.
   PubMed Web of Science ®Google Scholar
• Janowska A, Janus A, Kociszewski K, et al. New therapeutic options for hairy cell leukemia. Acta Haematol Pol. 2022;53:39–47.
   Google Scholar
• Andritsos LA, Dunavin N, Lozanski G, et al. Reduced dose pentostatin for initial management of hairy cell leukemia patients who have active infection or risk of hemorrhage is safe and effective. Haematologica. 2015;100:e18–20.
   PubMedGoogle Scholar
• Else M, Dearden CE, Catovsky D. Long-term follow-up after purine analogue therapy in hairy cell leukaemia. Best Pract Res Clin Haematol. 2015;28:217–229.
   PubMed Web of Science ®Google Scholar
• Robak T, Błasińska-Morawiec M, Błoński J, et al. 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland. Eur J Haematol. 1999;62:49–56.
   PubMed Web of Science ®Google Scholar
• Dearden CE, Else M, Catovsky D. Long-term results for pentostatin and cladribine treatment of hairy cell leukemia. Leuk Lymphoma. 2011;52(Suppl 2):21–24.
   PubMed Web of Science ®Google Scholar
• Broccoli A, Argnani L, Cross M, et al. A 3-decade multicenter European experience with cladribine as upfront treatment in 384 patients with hairy cell leukemia. Blood Adv. 2022;6:4224–4227.
   PubMed Web of Science ®Google Scholar
• Bohn JP, Neururer S, Pirklbauer M, et al. Hairy cell leukemia patients have a normal life expectancy-a 35-year single-center experience and comparison with the general population. Cancers (Basel). 2022;14:1242.
   PubMedGoogle Scholar
• Dinmohamed AG, Posthuma EFM, Visser O, et al. Relative survival reaches a plateau in hairy cell leukemia: a population-based analysis in The Netherlands. Blood. 2018;131:1380–1383.
   PubMedGoogle Scholar
• Bohn JP, Gastl G, Steurer M. Long-term treatment of hairy cell leukemia with interferon-α: still a viable therapeutic option. Memo. 2016;9:63–65.
   PubMedGoogle Scholar
• Assanto GM, Riemma C, Malaspina F, et al. The current role of interferon in hairy cell leukaemia: clinical and molecular aspects. Br J Haematol. 2021;194:78–82.
   PubMedGoogle Scholar
• Shenoi DP, Andritsos LA, Blachly JS, et al. Classic hairy cell leukemia complicated by pancytopenia and severe infection: a report of 3 cases treated with vemurafenib. Blood Adv. 2019;3:116–118.
   PubMedGoogle Scholar
• Robak E, Jesionek-Kupnicka D, Iskierka-Jazdzewska E, et al. Cutaneous leukocytoclastic vasculitis at diagnosis of hairy cell leukemia successfully treated with vemurafenib and rituximab. Leuk Res. 2021;104:106571.
   PubMedGoogle Scholar
• Paillassa J, Troussard X. Patients with relapsed/refractory hairy-cell leukemia. Cancer Rep (Hoboken). 2022;5:e1495.
   PubMedGoogle Scholar
• Zinzani PL, Pellegrini C, Stefoni V, et al. Hairy cell leukemia: evaluation of the long-term outcome in 121 patients. Cancer. 2010;116:4788–4792.
   PubMed Web of Science ®Google Scholar
• Chihara D, Arons E, Stetler-Stevenson M, et al. Randomized phase II study of first-line cladribine with concurrent or delayed rituximab in patients with hairy cell leukemia. J Clin Oncol. 2020;38:1527–1538.
   PubMed Web of Science ®Google Scholar
• Chihara D, Kantarjian H, O’Brien S, et al. Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial. Br J Haematol. 2016;174:760–766.
   PubMed Web of Science ®Google Scholar
• Burotto M, Stetler-Stevenson M, Arons E, et al. Bendamustine and rituximab in relapsed and refractory hairy cell leukemia. Clin Cancer Res. 2013;19:6313–6321.
   PubMed Web of Science ®Google Scholar
• Gerrie AS, Zypchen LN, Connors JM. Fludarabine and rituximab for relapsed or refractory hairy cell leukemia. Blood. 2012;119:1988–1991.
   PubMed Web of Science ®Google Scholar
• Thomas DA, O’Brien S, Cortes J, et al. Pilot study of rituximab in refractory or relapsed hairy cell leukemia (HCL) [abstract]. Blood. 1999;94:705a.
   Google Scholar
• Thomas DA, O’Brien S, Bueso-Ramos C, et al. Rituximab in relapsed or refractory hairy cell leukemia. Blood. 2003;102:3906–3911.
   PubMed Web of Science ®Google Scholar
• Hagberg H, Lundholm L. Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia. Br J Haematol. 2001;115:609–611.
   PubMed Web of Science ®Google Scholar
• Lauria F, Lenoci M, Annino L, et al. Efficacy of anti-CD20 monoclonal antibody, in the treatment of hairy cell leukemia. Haematologica. 2001;86:1046–1050.
   PubMed Web of Science ®Google Scholar
• Nieva J, Bethel K, Saven A. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood. 2003;102:810–813.
   PubMed Web of Science ®Google Scholar
• Zenhäusern R, Simcock M, Gratwohl A, et al. Rituximab in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine (SAKK 31/98). Haematologica. 2008;93:1426–1428.
   PubMed Web of Science ®Google Scholar
• Leclerc M, Suarez F, Noël MP, et al. Rituximab therapy for hairy cell leukemia: a retrospective study of 41 cases. Ann Hematol. 2015;94:89–95.
   PubMed Web of Science ®Google Scholar
• Edelmann J, Gribben JG. Obinutuzumab for the treatment of indolent lymphoma. Future Oncol. 2016;12:1769–1781.
   PubMedGoogle Scholar
• Bohn JP, Willenbacher E, Steurer M. Obinutuzumab in multidrug-resistant hairy cell leukemia. Ann Hematol. 2016;95:351–352.
   PubMedGoogle Scholar
• Al-Sarayfi D, Meeuwes FO, Munnink TO, et al. Successful treatment of hairy cell leukemia variant with obinutuzumab. Ann Hematol. 2022;101:703–704.
   PubMedGoogle Scholar
• Sadeghi N, Li HC. MRD-negative complete remission in relapsed refractory hairy cell leukemia with bendamustine and obinutuzumab. Ann Hematol. 2018;97:723–724.
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Pastan I. Development of recombinant immunotoxins for hairy cell leukemia. Biomolecules. 2020;10:1140.
   PubMedGoogle Scholar
• Kreitman RJ, Dearden C, Zinzani PL, et al. Moxetumomab pasudotox in heavily pretreated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial. J Hematol Oncol. 2021;14:35.
   PubMedGoogle Scholar
• Kreitman RJ, Stetler-Stevenson M, Margulies I, et al. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol. 2009;27:2983–2990.
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Tallman MS, Robak T, et al. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol. 2012;30:1822–1828.
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Wilson WH, Bergeron K, et al. Efficacy of the Anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med. 2001;345:241–247.
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Tallman MS, Robak T, et al. Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up. Blood. 2018;131:2331–2334.
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Dearden C, Zinzani PL, et al. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. Leukemia. 2018;32:1768–1777.
   PubMed Web of Science ®Google Scholar
• Bohn JP, Pircher A, Wanner D, et al. Low-dose vemurafenib in hairy cell leukemia patients with active infection. Am J Hematol. 2019;4:E180–E2.
   Google Scholar
• Konrat J, Rösler W, Roiss M, et al. BRAF inhibitor treatment of classical hairy cell leukemia allows successful vaccination against SARS-CoV-2. Ann Hematol. 2022 Dec 10;1–4. 10.1007/s00277-022-05026-z. Epub ahead of print
   Google Scholar
• Dietrich S, Glimm H, Andrulis M, et al. BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med. 2012;366:2038–2040.
   PubMed Web of Science ®Google Scholar
• Robak T, Janus A, Jamroziak K, et al. Vemurafenib and rituximab in patients with hairy cell leukemia previously treated with Moxetumomab pasudotox. J Clin Med. 2021;10:280076.
   Google Scholar
• Tiacci E, Park JH, De Carolis L, et al. Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia. N Engl J Med. 2015;373:1733–1747.
   PubMed Web of Science ®Google Scholar
• Dietrich S, Pircher A, Endris V, et al. BRAF inhibition in hairy cell leukemia with low- dose vemurafenib. Blood. 2016;127:2847–2855.
   PubMed Web of Science ®Google Scholar
• Troussard X, Montané L, Tiab M, et al. Vemurafenib in advanced patients with hairy cell leukemia (HCL): results of the Acsé phase II trial. Blood. 2017;130(Suppl 1):156.
   PubMedGoogle Scholar
• Handa S, Lee JO, Derkach A, et al. Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy. Blood. 2022;140:2663–2671.
   PubMedGoogle Scholar
• Bhangoo MS, Saven A. Secondary malignancies after treatment with single-agent vemurafenib in two patients with refractory hairy cell leukemia. Leuk Lymphoma. 2019;60:1331–1333.
   PubMed Web of Science ®Google Scholar
• Tiacci E, De Carolis L, Simonetti E, et al. Vemurafenib plus rituximab in refractory or relapsed hairy-cell leukemia. N Engl J Med. 2021;384:1810–1823.
   PubMedGoogle Scholar
• Park JH, Shukla M, Salcedo JM, et al. First line chemo-free therapy with the BRAF inhibitor vemurafenib combined with obinutuzumab is effective in patients with HCL. Blood. 2019;134(Suppl 1):3998.
   Google Scholar
• Tiacci E, De Carolis L, Simonetti E, et al. Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial. Leukemia. 2021;35:3314–3318.
   PubMedGoogle Scholar
• Caeser R, Collord G, Yao WQ, et al. Targeting MEK in vemurafenib-resistant hairy cell leukemia. Leukemia. 2019 Feb;33:541–545.
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Moreau P, Ravandi F, et al. Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia. Blood. 2022;141:996–1006. Sep 15:blood.2021013658. Online ahead of print.
   Google Scholar
• Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372:30–39.
   PubMed Web of Science ®Google Scholar
• Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377:1813–1823.
   PubMed Web of Science ®Google Scholar
• Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J Clin Oncol. 2018;36:7–13.
   PubMed Web of Science ®Google Scholar
• Planchard D, Besse B, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open label, multicentre phase 2 trial. Lancet Oncol. 2016;17:984–993.
   PubMed Web of Science ®Google Scholar
• Weston-Bell NJ, Hendriks D, Sugiyarto G, et al. Hairy cell leukemia cell lines expressing annexin A1 and displaying B-cell receptor signals characteristic of primary tumor cells lack the signature BRAF mutation to reveal unrepresentative origins. Leukemia. 2013;27:241–245.
   PubMedGoogle Scholar
• Rogers KA, Andritsos LA, Wei L, et al. Phase 2 study of ibrutinib in classic and variant hairy cell leukemia. Blood. 2021;137:3473–3483.
   PubMedGoogle Scholar
• Korycka-Wolowiec A, Wolowiec D, Kubiak-Mlonka A, et al. Venetoclax in the treatment of chronic lymphocytic leukemia. Expert Opin Drug Metab Toxicol. 2019;15:353–366.
   PubMed Web of Science ®Google Scholar
• Brancati S, Gozzo L, Romano GL, et al. Venetoclax in relapsed/refractory acute myeloid leukemia: are supporting evidences enough? Cancers (Basel). 2022;4:22.
   Google Scholar
• Vereertbrugghen A, Colado A, Gargiulo E, et al. In vitro sensitivity to venetoclax and microenvironment protection in hairy cell leukemia. Front Oncol. 2021;11:2595.
   Google Scholar
• Jain P, Kanagal-Shamanna R, Konoplev S, et al. Biclonal IGHV-4-34 hairy cell leukemia variant and CLL - successful treatment with ibrutinib and venetoclax. Am J Hematol. 2018;93:1568–1569.
   PubMed Web of Science ®Google Scholar
• Tiacci E, De Carolis L, Santi A, et al. Venetoclax in refractory or relapsed hairy cell leukemia. N Engl J Med. 2023;388:952–954.
   Google Scholar
• Yin Z, Zhang Y, Wang X. Advances in chimeric antigen receptor T-cell therapy for B cell non-Hodgkin lymphoma. Biomark Res. 2021;9:58.
   PubMed Web of Science ®Google Scholar
• June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;4379:64–73.
   Google Scholar
• Savani M, Oluwole O, Dholaria B. New targets for CAR T therapy in hematologic malignancies. Best Pract Res Clin Haematol. 2021;34:101277.
   PubMedGoogle Scholar
• Cheever MA, Fefer A, Greenberg PD, et al. Treatment of hairy-cell leukemia wit chemoradiotherapy and identical-twin bone-marrow transplantation. N Engl J Med. 1982;307:479–481.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Bonifazi F, Pellegrini C, et al. Hairy cell leukemia: allogeneic transplantation could be an optimal option in selected patients. Clin Lymphoma Myeloma Leuk. 2012;12:287–289.
   PubMed Web of Science ®Google Scholar
• Kiyasu J, Shiratsuchi M, Ohtsuka R, et al. Achievement of complete remission of refractory hairy cell leukemia by rituximab progressing after allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2009;89:403–405.
   PubMedGoogle Scholar
• Toborek M, Wieczorkiewicz-Kabut A, Semeńczuk G, et al. The first allogeneic stem cell transplantation in Poland in a patient with refractory hairy cell leukemia. Hematologia. 2020;11:45–49.
   Google Scholar
• Chihara D, Gras L, Zinger N, et al. Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience. Haematologica. 2022 Dec 22. 10.3324/haematol.2022.281754. Epub ahead of print.
   PubMedGoogle Scholar
• Kreitman R, Wyndham Wilson W, Katherine R, et al. Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia. Clin Cancer Res. 2013;19:6873–6881.
   PubMed Web of Science ®Google Scholar
• Chihara D, Arons E, Stetler-Stevenson M, et al. Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant. Blood Adv. 2021;5:4807–4816.
   PubMedGoogle Scholar
• Visentin A, Imbergamo S, Frezzato F, et al. Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: a report of three cases. Oncotarget. 2017;8:110727–110731.
   PubMedGoogle Scholar
• Matutes E, Wotherspoon A, Brito-Babapulle V, et al. The natural history and clinico- pathological features of the variant form of hairy cell leukemia. Leukemia. 2001;15:184–186.
   PubMed Web of Science ®Google Scholar
• Liu Q, Harris N, Epperla N, et al. Current and emerging therapeutic options for hairy cell leukemia variant. Onco Targets Ther. 2021;14:1797–1805.
   PubMed Web of Science ®Google Scholar
• Bohn JP, Wanner D, Steurer M. Ibrutinib for relapsed refractory hairy cell leukemia variant. Leuk Lymphoma. 2017;58:1224–1226.
   PubMed Web of Science ®Google Scholar
• Andritsos LA, Grieselhuber NR, Anghelina M, et al. Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia. Leuk Lymphoma. 2018;59:1008–1011.
   PubMed Web of Science ®Google Scholar
• Bohn JP, Wanner D, Steurer M. Ibrutinib for relapsed refractory hairy cell leukemia variant. Leuk Lymphoma. 2017;58:1224–1226.
   PubMed Web of Science ®Google Scholar
• Jain P, Kanagal-Shamanna R, Konoplev S, et al. Biclonal IGHV-4-34 hairy cell leukemia variant and CLL – successful treatment with ibrutinib and venetoclax. Am J Hematol. 2018;93:1568–1569.
   PubMed Web of Science ®Google Scholar
• Visentin A, Imbergamo S, Trimarco V, et al. Ibrutinib in relapsed hairy cell leukemia variant: a case report and review of the literature. Hematol Oncol. 2020;38:823–826.
   PubMed Web of Science ®Google Scholar
• Mason EF, Brown RD, Szeto DP, et al. Detection of activating MAP2K1 mutations in atypical hairy cell leukemia and hairy cell leukemia variant. Leuk Lymphoma. 2017;58:233–236.
   PubMed Web of Science ®Google Scholar
• Andritsos LA, Grieselhuber NR, Anghelina M. Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia. Leuk Lymphoma. 2018;59:1008–1011.
   PubMed Web of Science ®Google Scholar
• Busemann C, Schüler F, Krüger W, et al. Late extramedullary relapse after allogeneic transplantation in a case of variant hairy cell leukaemia. Bone Marrow Transplant. 2010;45:1117–1118.
   PubMedGoogle Scholar
• Liu Q, Harris N, Epperla N, et al. Current and emerging therapeutic options for hairy cell leukemia variant. Onco Targets Ther. 2021;14:1797–1805.
   PubMed Web of Science ®Google Scholar
• Durham BH, Getta B, Dietrich S, et al. The del(17p)/TP53 mutation is more common in HCLv than in clasic HCL and was observed even in 30% to 40% of patients. Blood. 2017;130:1644–1648.
   PubMed Web of Science ®Google Scholar
• Hockley SL, Else M, Morilla A, et al. The prognostic impact of clinical and molecular features in hairy cell leukaemia variant and splenic marginal zone lymphoma. Br J Haematol. 2012;158:347–454.
   PubMed Web of Science ®Google Scholar
• Chihara D, Arons E, Stetler-Stevenson M, et al. Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant. Blood Adv. 2021;5:4807–4816.
   PubMedGoogle Scholar
• Ravandi F, Kreitman RJ, Tiacci E, et al. Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia. Blood Cancer J. 2022;12(12):165.
   PubMedGoogle Scholar
• Robak T, Robak P. Measurable residual disease in hairy cell leukemia: technical considerations and clinical significance. Front Oncol. 2022;12:976374.
   PubMedGoogle Scholar
• Andritsos LA, Anghelina M, Neal J, et al. Development of a distributed international patient data registry for hairy cell leukemia. Leuk Lymphoma. 2022;63:3021–3031.
   PubMedGoogle Scholar